A group of more than 100 Democratic lawmakers sent a letter to President Donald Trump on Friday warning about the potential ...

Our writer Ken Hall evaluates two defensive dividend payers in the FTSE 100 that he thinks investors should consider buying ...

Gilead Sciences takes a hit after a Wall Street Journal reports state that the Trump administration is looking to slash ...

We suggest that investors who own GSK's stock remain invested for now, considering its sales and profits are expected to continue improving in the coming years.

The Department of Health and Human Services (HHS) is reportedly poised to slash funding for domestic HIV prevention at the ...

Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is largely due to excitement over its [long-acting HIV prevention drug]( ...

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

Gilead Sciences stock declined Wednesday after The Wall Street Journal reported the Department of Health and Human Services ...

The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.

HHS is considering major cuts to federal HIV prevention funding as part of a CDC reorganization, potentially affecting programs like PrEP. Experts warn the move could hinder efforts to combat the ...

The Health and Human Services Department is weighing plans to drastically cut funding for domestic HIV prevention, The Wall Street Journal reported. + The cuts could af ...

Gilead Sciences (GILD) stock fell after The Wall Street Journal reported that the Health and Human Services Department is looking at ...